Our top pick for
Identiv Inc is a computer hardware business based in the US. Identiv shares (INVE) are listed on the NASDAQ and all prices are listed in US Dollars. Identiv employs 326 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$17.52|
|52-week range||$5.91 - $21.18|
|50-day moving average||$18.73|
|200-day moving average||$16.22|
|Wall St. target price||$22.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.02|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-3.20%|
|1 month (2021-09-24)||-11.56%|
|3 months (2021-07-23)||11.81%|
|6 months (2021-04-23)||20.25%|
|1 year (2020-10-23)||171.84%|
|2 years (2019-10-24)||290.20%|
|3 years (2018-10-24)||203.64%|
|5 years (2016-10-24)||750.49%|
Valuing Identiv stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Identiv's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Identiv's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.6 million.
The EBITDA is a measure of a Identiv's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$95.9 million|
|Operating margin TTM||0.02%|
|Gross profit TTM||$33.7 million|
|Return on assets TTM||0.01%|
|Return on equity TTM||1.3%|
|Market capitalisation||$401.1 million|
TTM: trailing 12 months
There are currently 783,411 Identiv shares held short by investors – that's known as Identiv's "short interest". This figure is 15.9% up from 676,122 last month.
There are a few different ways that this level of interest in shorting Identiv shares can be evaluated.
Identiv's "short interest ratio" (SIR) is the quantity of Identiv shares currently shorted divided by the average quantity of Identiv shares traded daily (recently around 169937.31019523). Identiv's SIR currently stands at 4.61. In other words for every 100,000 Identiv shares traded daily on the market, roughly 4610 shares are currently held short.
However Identiv's short interest can also be evaluated against the total number of Identiv shares, or, against the total number of tradable Identiv shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Identiv's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Identiv shares in existence, roughly 40 shares are currently held short) or 0.0439% of the tradable shares (for every 100,000 tradable Identiv shares, roughly 44 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Identiv.
Find out more about how you can short Identiv stock.
We're not expecting Identiv to pay a dividend over the next 12 months.
Identiv's shares were split on a 1:10 basis on 26 May 2014. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Identiv shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Identiv shares which in turn could have impacted Identiv's share price.
Over the last 12 months, Identiv's shares have ranged in value from as little as $5.91 up to $21.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Identiv's is 1.737. This would suggest that Identiv's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Identiv, Inc. operates as a security technology company that secures data, physical places, and things in the Americas, Europe, the Middle East, and the Asia-Pacific. It operates in two segments, Premises and Identity. The Premises segment offers solutions for premises security market, such as access control, video surveillance, analytics, audio, access readers, and identities to government facilities, schools, utilities, hospitals, stores, shops, and apartment buildings. The Identity segment provides products and solutions that enables secure access to information serving the logical access and cyber security markets, protecting connected objects, and information using radio-frequency identification embedded security. It sells its products through dealers, systems integrators, value added resellers, and resellers. The company was formerly known as Identive Group, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.